Performance characteristics of the cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Dorman, Susan E ^a   Chihota, Violet N ^b   Lewis, James J ^b,c   Shah, Maunank ^a   Clark, David ^b   Grant, Alison D ^c   Churchyard, Gavin J ^b,c,d   Fielding, Katherine L ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AURUM INSTITUTE   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACID FAST BACTERIUM; ADULT; ARTICLE; BACTERIUM EXAMINATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HEALTH SURVEY; HUMAN; LIQUID CULTURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MINING; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM CULTURE; SPUTUM SMEAR;

ADULT; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84865048285     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043307     Document Type: Article

References (25)

1. Dye C, Bassili A, Bierrenbach AL, Broekmans JF, Chadha VK, et al. (2008) Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis. 8: 233-243.
2. Glaziou P, van der Werf MJ, Onozaki I, Dye C, Borgdorff MW, et al. (2008) Tuberculosis prevalence surveys: rationale and cost. Int J Tuberc Lung Dis. 12: 1003-1008.
3. van der Werf MJ, Enarson DA, Borgdorff MW, (2008) How to identify tuberculosis cases in a prevalence survey. Int J Tuberc Lung Dis. 12: 1255-1260.
4. World Health Organization. Tuberculosis prevalence surveys: a handbook. WHO/HTM/TB/2010.17. Available: www.who.int/tb/advisory_bodies/impact_measurement_taskforce/resources_documents/thelimebook/en/index.html. Accessed January 2, 2012.
5. Fielding KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, et al. (2011) Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials. 32: 382-392.
6. Ayles HM, Sismanidis C, Beyers N, Hayes RJ, Godfrey-Faussett P, (2008) ZAMSTAR, The Zambia South Africa TB and HIV Reduction Study: design of a 2×2 factorial community randomized trial. Trials. 9: 63.
7. Ayles H, Schaap A, Nota A, Sismanidis C, Tembwe R, et al. (2009) Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS One. 4: e5602.
8. Corbett EL, Bandason T, Duong T, Dauya E, Makamure B, et al. (2010) Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 376: 1244-1253.
9. Siddiqi K, Lambert ML, Walley J, (2003) Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 3: 288-296.
10. Perkins MD, Cunningham J, (2007) Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis. 196: S15-S27.
11. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, et al. (2006) Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 6: 570-581.
12. Helb D, Jones M, Story E, Boehme C, Wallace E, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 48: 229-237.
13. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 363: 1005-1015.
14. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 377: 1495-1505.
15. Blakemore R, Story E, Helb D, Kop J, Banada P, et al. (2010) Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 48: 2495-2501.
16. Van Rie A, Mellet K, John MA, Scott L, Page-Shipp L, et al. (2012) False-positive rifampicin resistance on Xpert MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis. 16: 206-208.
17. Marlowe EM, Novak-Weekley SM, Cumpio J, Sharp SE, Momeny MA, et al. (2011) Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol. 49: 1621-1623.
18. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, et al. (2011) Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 184: 132-140.
19. Banada PP, Sivasubramani SK, Blakemore R, Boehme C, Perkins MD, et al. (2010) Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol. 48: 3551-3557.
20. Kent PT, Kubica GP (1985) Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: Centers for Disease Control.
21. Global TB Programme, World Health Organization. Laboratory services in TB control, Part II: Microscopy. WHO/TB/98.258. Available: http://whqlibdoc.who.int/hq/1998/WHO_TB_98.258_(part2).pdf. Accessed January 2, 2012.
22. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, et al. (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 8(7): e1001067.
23. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational "How-to" practical considerations. WHO/HTM/TB/2011.2. Available: http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf. Accessed January 2, 2012.
24. Burman WJ, Reves RR, (2000) Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment. Clin Infect Dis. 31: 1390-1395.
25. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, et al. (2011) Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 8(11): e1001120.